When patients present with STEMI-related cardiogenic shock, treatment with the Impella CP appears to make a positive impact that lasts for at least a decade.

The European Society of Cardiology had nearly twice as many attendees as ACC this year, as the European meeting secures its place as the largest cardiology meeting in the world.

The Varipulse PFA platform, which has already received FDA and CE mark approval, was linked to an adverse event rate of just 0.6%. 

GLP-1 drugs have been taking the United States by storm in recent years. According to a new study of more than 90,000 patients, some of these medications can also make a big impact on reducing adverse heart failure outcomes.

One researcher described the study's findings as "one of the most significant advances in heart attack treatment in decades.”

New data out of ESC Congress 2025 suggest care teams can take a more minimalist approach during a majority of TAVR cases and only treat patients with local anesthesia. In some cases, however, sedation will still be necessary. 

Abbott's TAVR valve now has CE mark approval for treating low-, intermediate- and high-risk patients who present with symptomatic severe aortic stenosis. The news comes as new data on the valve's safety and effectiveness were just published in JACC: Cardiovascular Interventions.

The European Society of Cardiology 2025 congress includes 10 Hot Line sessions and 28 late-breaking science sessions to showcase the latest science.